Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Experimentally induced puromycine aminonucleoside nephrosis (PAN) in rats: evaluation of angiogenic protein platelet-derived endothelial cell growth factor (PD-ECGF) expression in glomeruli

Autor: Seckin Ismail, Uzunalan Mumin, Pekpak Meltem, Kokturk Sibel, Sonmez Huseyin, Öztürk Zeynep, Demirci Sibel, Yaprak Elif

Publikováno v: Journal of Biomedical Science, Vol 19, Iss 1, p 24 (2012)

Abstract Background In experimentally induced puromycine aminonucleoside nephrosis (PAN) animal models, nephrotic syndrome with minimal change disease and focal and segmental sclerosis-like nephritis similar to that in human is demonstrated; however,

Externí odkaz: https://doaj.org/article/5eec0ea2db4a467a915380c9afd1aff7

Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.

Autor: Merola JF; Department of Dermatology, Medicine and Rheumatology, UT Southwestern Medical Center, Dallas, Texas. Electronic address: joseph.merola@gmail.com., Chiou AS; Department of Dermatology, Stanford University, Palo Alto, California., During E; Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California; Division of Sleep Medicine, Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California., Foley P; Skin Health Institute, Carlton, Victoria, Australia; Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia., Wu J; Sanofi, Bridgewater, New Jersey., Ardeleanu M; Regeneron Pharmaceuticals Inc., Tarrytown, New York., Ozturk ZE; Sanofi, Cambridge, Massachusetts.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Jul 14. Date of Electronic Publication: 2024 Jul 14.

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.

Autor: Merola JF; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chiou AS; Department of Dermatology, Stanford University, Palo Alto, CA, USA., During E; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA.; Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University, Palo Alto, CA, USA., Costanzo A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Foley P; Skin Health Institute, Carlton, VIC, Australia.; Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.; Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Alfalasi A; Al Safa Dermatology Clinic, Dubai, United Arab Emirates., Gogate S; Colorado Allergy & Asthma Centers, Denver, CO, USA., Pinter A; Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Dodiuk-Gad R; Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.; Dermatology Department, Emek Medical Center, Afula, Israel., Simon D; Department of Dermatology, Universitätsspital Bern, Bern, Switzerland., Tauber M; Department of Allergology and Clinical Immunology, CIRI Inserm U1111, Lyon Sud Hospital, Lyon, France., Weller R; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK., Pereyra-Rodriguez JJ; Dermatology Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain., Ardeleanu M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Wu J; Sanofi, Bridgewater, NJ, USA., Ozturk ZE; Sanofi, Cambridge, MA, USA.

Publikováno v: The British journal of dermatology [Br J Dermatol] 2023 Nov 16; Vol. 189 (6), pp. 685-694.

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.

Autor: Bruin-Weller M; National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands., Pink AE; St. John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Patrizi A; Department of Dermatology, IRCCS Policlinico di S. Orsola, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy., Gimenez-Arnau AM; Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain., Agner T; Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark., Roquet-Gravy PP; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium., Ferrucci SM; Department of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Arenberger P; Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic., Svensson A; Skåne University Hospital, Malmo, Sweden., Schuttelaar MLA; Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Nosbaum A; Allergy and Clinical Immunology Department, University of Lyon, Lyon Sud University Hospital, Pierre Benite, France., Jayawardena S; Sanofi, Bridgewater, NJ, USA., Rizova E; Sanofi Genzyme, Cambridge, MA, USA., Ardeleanu M; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA., Eckert L; Sanofi, Chilly-Mazarin, France., Ozturk ZE; Sanofi Genzyme, Cambridge, MA, USA.

Publikováno v: The Journal of dermatological treatment [J Dermatolog Treat] 2021 Mar; Vol. 32 (2), pp. 164-173. Date of Electronic Publication: 2021 Jan 18.